RSV patients treated with antiviral drug S-337395 showed statistically significant reduction in viral load S-337395 is ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

LONDON - Shionogi & Co., Ltd. (TYO ... oral antiviral candidate targeting Respiratory Syncytial Virus (RSV), conducted by hVIVO plc, a leader in human challenge clinical trials.

The trial demonstrated a significant reduction in viral load for Shionogi's investigational oral RSV antiviral candidate, S-337395. S-337395, which has received Fast Track designation from the U.S ...

R&D expenses increased 9.4% year-over-year, reflecting aggressive investment in high-priority development pipelines, including clinical trials for COVID-19 and RSV-related treatments. Hidemaru ...

LONDON - Shionogi & Co., Ltd. (TYO:4507) has reported positive outcomes from its Phase 2a human challenge trial for an investigational oral antiviral candidate targeting Respiratory Syncytial Virus ...

(Sharecast News) - hVIVO reported positive results from a phase 2a respiratory syncytial virus (RSV) human challenge trial conducted on behalf of Shionogi on Wednesday. The AIM-traded firm said ...